WHO Endorses New Obesity Treatment Options
The World Health Organization (WHO) has endorsed GLP-1 receptor agonists, including semaglutide and tirzepatide, as effective treatments for obesity. These drugs mimic appetite-regulating hormones and offer a new approach to combating obesity, which affects 890 million adults globally. Obesity's economic impact is significant, with global healthcare costs expected to reach trillion by 2030. Semaglutide-based medications like Wegovy and Zepbound are revolutionizing treatment options, with generic versions under development. WHO plans to issue guidelines in 2025 for their safe use. This marks a milestone in global efforts to tackle obesity through advanced medical interventions.
Related Posts
If you like this post, please share your feedback in the comments section below so that we will upload more posts like this.
Responses